Testing a new moisturizer for eczema in different age groups
Part of Brain & nervous system, Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new moisturizing product (RV4421B) for people with mild to moderate atopic dermatitis (eczema). Participants will use the product along with their usual steroid cream for 12 weeks to see how well it works and if it’s safe for different ages, from babies to adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 3 months old. There are three age groups: infants (3–23 months), children (24 months–12 years), and teenagers and adults (13+).
- You must have a doctor’s diagnosis of atopic dermatitis (a common type of eczema).
- Your eczema should be mild to moderate, and the affected skin should cover no more than 30% of your body.
- You need to be using a prescription steroid cream on your eczema patches at the time you join, and have been using it for at least 1 day.
- You cannot have eczema on the diaper area (if you’re an infant or child), or have any other skin condition that might interfere with the study.
- You cannot be using certain other treatments like strong immune-suppressing drugs, phototherapy, or antibiotics on your skin within a few weeks before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new dermocosmetic cream for children with eczema. It looks at how well the cream works and how gentle it is on the skin, after the child uses a prescribed steroid cream to calm a flare-up.
This trial tests whether a cosmetic cream can reduce eczema flare-ups and is comfortable/safe to use on very dry, irritated, eczema-prone skin. It’s mainly for children who have had recent flare-ups and moderate eczema severity.
This trial compares two moisturizers for people with eczema (moderate rash) and healthy volunteers. It looks at how well they work and how the skin tolerates them after using a steroid cream.
This study tests a new medication called VC005 to treat atopic dermatitis (eczema)—a skin condition causing itching, redness, and inflammation. Researchers want to see if VC005 can safely reduce symptoms in people aged 12 and older with mild-to-moderate cases.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.